Type | Positions | Description |
Chain |
1 – 393 |
Cellular tumor antigen p53 |
Region |
300 – 393 |
Interaction with CARM1 |
Region |
351 – 393 |
Disordered |
Region |
368 – 387 |
Basic (repression of DNA-binding) |
Region |
374 – 393 |
Interaction with MORN3 |
Compositional bias |
366 – 380 |
Basic residues |
Modified residue |
370 – 370 |
N6,N6-dimethyllysine; alternate |
Modified residue |
370 – 370 |
N6-methyllysine; by SMYD2; alternate |
Modified residue |
372 – 372 |
N6-methyllysine; by SETD7 |
Modified residue |
373 – 373 |
N6,N6-dimethyllysine; by EHMT1 and EHMT2; alternate |
Modified residue |
373 – 373 |
N6-acetyllysine; alternate |
Modified residue |
381 – 381 |
N6-acetyllysine |
Modified residue |
382 – 382 |
N6,N6-dimethyllysine; alternate |
Modified residue |
382 – 382 |
N6-acetyllysine; by KAT6A; alternate |
Modified residue |
382 – 382 |
N6-methyllysine; by KMT5A; alternate |
Modified residue |
392 – 392 |
Phosphoserine; by CK2, CDK2 and NUAK1 |
Cross |
386 – 386 |
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO) |
Alternative sequence |
342 – 393 |
Missing. In isoform 2, isoform 5 and isoform 8. |
Alternative sequence |
347 – 393 |
Missing. In isoform 3, isoform 6 and isoform 9. |
Mutagenesis |
359 – 359 |
P -> D. Abolishes binding to USP7. |
Mutagenesis |
361 – 361 |
G -> E. Abolishes binding to USP7. |
Mutagenesis |
362 – 362 |
S -> A. Abolishes binding to USP7. |
Mutagenesis |
370 – 370 |
K -> R. Induces a decrease in methylation by SMYD2. |
Mutagenesis |
372 – 372 |
K -> R. Induces a decrease in protein stabilization. |
Mutagenesis |
373 – 373 |
K -> R. Abolishes dimethylation by EHMT1 and EHMT2. |
Mutagenesis |
381 – 381 |
K -> Q. Mimics acetylation, leading to increased stability. |
Mutagenesis |
381 – 381 |
K -> R. Decreased acetylation. |
Mutagenesis |
382 – 382 |
K -> A. Abolishes acetylation by CREBBP. |
Mutagenesis |
382 – 382 |
K -> R. Abolishes monomethylation by KMT5A. |
Mutagenesis |
383 – 383 |
L -> A. Abolishes S-315 phosphorylation by CDK2/cyclin A. |
Mutagenesis |
385 – 385 |
F -> A. Reduced SUMO1 conjugation. |
Mutagenesis |
386 – 386 |
K -> A. Abolishes SUMO1 conjugation, in vitro and in vivo. |
Mutagenesis |
387 – 387 |
T -> A. No effect SUMO1 conjugation. |
Mutagenesis |
388 – 388 |
E -> A. Abolishes SUMO1 conjugation. |
Helix |
375 – 380 |
|